Mutagenic activity of radiosensitizers

Area of Science:

• Chemical mutagenesis
• Radiosensitizer development
• Toxicology

Background:

• Nitroimidazoles are a class of compounds investigated for their potential as radiosensitizers in cancer therapy.
• Assessing the mutagenicity of novel chemical entities is crucial for their safe development and application.

Purpose of the Study:

• To evaluate the mutagenic potential of seven radiosensitizer candidates, including six nitroimidazole derivatives and one imidazole derivative.
• To identify specific mutagenic mechanisms, such as base pair substitutions, frameshift mutations, and epigenetic alterations.

Main Methods:

• Utilized three standard short-term mutagenicity assays: the Ames test (bacterial reverse mutation assay), prophage lambda induction, and the tryptophan reversion test.
• Tested seven compounds, coded P1 to P6, with a focus on nitroimidazole derivatives.

Main Results:

• Five of the seven investigated compounds demonstrated no mutagenic activity across the tested assays.
• Compound P1, a nitroimidazole derivative, was found to induce base pair substitution mutations.
• Metronidazole, another nitroimidazole derivative, exhibited mutagenicity, inducing both base pair substitutions and frameshift mutations. It also tested positive in the prophage lambda induction test, indicating potential epigenetic effects.

Conclusions:

• The majority of the investigated nitroimidazole derivatives (5 out of 7) are not mutagenic, suggesting a favorable safety profile for further development.
• Metronidazole displays a clear mutagenic profile, inducing both gene mutations and potentially epigenetic changes, warranting careful consideration for its use.
• The study highlights the importance of comprehensive genotoxicity testing for radiosensitizer candidates, as mutagenic potential can vary significantly within chemical classes.